Live
The US health regulator has given its approval to Zydus Cadila for marketing its anti-hypertensive olmesartan medoxomil tablets in the American market.
Cadila Healthcare has said in a BSE filing that the company has received “final approval from the United States Food and Drug Administration (USFDA) to market olmesartan medoxomil tablets in the strengths of 5 mg, 20 mg, 40 mg.”
It added that the drug is an anti-hypertensive and will be produced at the group’s formulations manufacturing facility in Ahmedabad.
